荷兰 - 荷兰文 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mylan b.v. krijgsman 20 1186 dm amstelveen - lamotrigine 200 mg/stuk - dispergeerbare tablet - cellulose, microkristallijn (e 460(i)) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; natriumzetmeelglycolaat ; povidon (e 1201) ; saccharoide natrium x-water (e 954) ; siliciumdioxide (e 551), cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; natriumzetmeelglycolaat ; povidon (e 1201) ; saccharoide natrium x-water (e 954) ; siliciumdioxide (e 551), cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; natriumzetmeelglycolaat (e468) ; povidon (e 1201) ; saccharoide natrium x-water (e 954) ; siliciumdioxide (e 551), - lamotrigine

荷兰 - 荷兰文 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mylan b.v. krijgsman 20 1186 dm amstelveen - lamotrigine 25 mg/stuk - dispergeerbare tablet - cellulose, microkristallijn (e 460(i)) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; natriumzetmeelglycolaat ; povidon (e 1201) ; saccharoide natrium x-water (e 954) ; siliciumdioxide (e 551), cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; natriumzetmeelglycolaat ; povidon (e 1201) ; saccharoide natrium x-water (e 954) ; siliciumdioxide (e 551), cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; natriumzetmeelglycolaat (e468) ; povidon (e 1201) ; saccharoide natrium x-water (e 954) ; siliciumdioxide (e 551), - lamotrigine

荷兰 - 荷兰文 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mylan b.v. krijgsman 20 1186 dm amstelveen - lamotrigine 50 mg/stuk - dispergeerbare tablet - cellulose, microkristallijn (e 460(i)) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; natriumzetmeelglycolaat ; povidon (e 1201) ; saccharoide natrium x-water (e 954) ; siliciumdioxide (e 551), cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; natriumzetmeelglycolaat ; povidon (e 1201) ; saccharoide natrium x-water (e 954) ; siliciumdioxide (e 551), cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; natriumzetmeelglycolaat (e468) ; povidon (e 1201) ; saccharoide natrium x-water (e 954) ; siliciumdioxide (e 551), - lamotrigine

欧盟 - 荷兰文 - EMA (European Medicines Agency)

roche registration gmbh - ocrelizumab - multiple sclerose - immunosuppressiva - behandeling van volwassen patiënten met relapsing vormen van multiple sclerose (rms) met actieve ziekte gedefinieerd door klinische of beeldvormende kenmerken. de behandeling van volwassen patiënten met vroege primair progressieve multiple sclerose (ppms) in termen van de ziekte, de duur en de mate van invaliditeit, en imaging kenmerken kenmerk van inflammatoire activiteit.

欧盟 - 荷兰文 - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastische middelen - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq als monotherapie is geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderd of gemetastaseerd niet-kleincellig longcarcinoom na voorafgaande chemotherapie. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq als monotherapie is geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderd of gemetastaseerd niet-kleincellig longcarcinoom na voorafgaande chemotherapie. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

荷兰 - 荷兰文 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dr. fisher farma b.v. - lamotrigine - dispergeerbare tablet, kauwtablet - aluminiummagnesiumsilicaat ; calciumcarbonaat (e 170) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; povidon k 30 (e 1201) ; saccharoide natrium x-water (e 954) ; zwarte bessen smaakstof 502.009 / ap 0551, aluminiummagnesiumsilicaat ; calciumcarbonaat (e 170) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; povidon k 30 (e 1201) ; saccharoide natrium x-water (e 954) ; zwarte bessen smaakstof 502.009 / ap 0551, - lamotrigine

欧盟 - 荷兰文 - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemophilia a - antihemorragica - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra kan worden gebruikt in alle leeftijd groepen.

荷兰 - 荷兰文 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - lamotrigine 25 mg/stuk - dispergeerbare tablet, kauwtablet - aluminiummagnesiumsilicaat ; calciumcarbonaat (e 170) ; hydroxypropylcellulose, laag gesubstitueerd (e 463a) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; povidon k 30 (e 1201) ; saccharoide natrium x-water (e 954) ; zwarte bessen smaakstof 502.009 / ap 0551, aluminiummagnesiumsilicaat ; calciumcarbonaat (e 170) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; povidon k 30 (e 1201) ; saccharoide natrium x-water (e 954) ; zwarte bessen smaakstof 502.009 / ap 0551 - lamotrigine

荷兰 - 荷兰文 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - lamotrigine 5 mg/stuk - dispergeerbare tablet, kauwtablet - aluminiummagnesiumsilicaat ; calciumcarbonaat (e 170) ; hydroxypropylcellulose, laag gesubstitueerd (e 463a) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; povidon k 30 (e 1201) ; saccharoide natrium x-water (e 954) ; zwarte bessen smaakstof 502.009 / ap 0551, aluminiummagnesiumsilicaat ; calciumcarbonaat (e 170) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; povidon k 30 (e 1201) ; saccharoide natrium x-water (e 954) ; zwarte bessen smaakstof 502.009 / ap 0551 - lamotrigine

欧盟 - 荷兰文 - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - lymfoom, b-cel - antineoplastische middelen - polivy in combinatie met bendamustine en rituximab is geïndiceerd voor de behandeling van volwassen patiënten met recidiverende/refractaire diffuus grootcellig b-cel lymfoom (dlbcl) die geen kandidaat zijn voor een hematopoëtische stamceltransplantatie. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).